SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.

Trial Details

NCT ID
NCT05990192
Phase
PHASE2
Sponsor
Institute of Cancer Research, United Kingdom
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Niraparib oral capsule
  • SBRT
Locations (sample)
  • Leeds, Leeds, United Kingdom|53.79648,-1.54785
  • Leicester, Leicester, United Kingdom|52.6386,-1.13169
  • Manchester, Manchester, United Kingdom|53.48095,-2.23743
  • Edinburgh, Scotland, United Kingdom|55.95206,-3.19648
  • Sutton, Surrey, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • Patients ≥ 18 years of age.
  • Histologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer. (if cytology report includes immunohistochemistry confirm…
  • Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient…
  • Minimum duration of 6 months PARP inhibitor therapy as first line therapy or treatment for recurrent disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →